A multicenter study compared the GV between DPP4 inhibitor and glimepiride groups, and found that DPP4 inhibitors were more effective than glimepiride in reducing GV as initial combination therapy with metformin in patients with type 2 diabetes [100]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.